Prolonged treatment with interferon in patients with histologically mild chronic hepatitis C: A decision analysis

Journal of Viral Hepatitis

Volumn 5, Issue 5, 1998, Pages 313-321

  Davis, G L ^a,e   Beck, J R ^b   Farrell, G ^c   Poynard, T ^d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cost effectiveness analysis; Decision making; Hepatitis C; IFN

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DISEASE SEVERITY; DRUG COST; DRUG RESPONSE; HEALTH CARE COST; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0031663113     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00119.x     Document Type: Article

References (33)

1. Davis GL, Lau JYN, Lim HL. Therapy for chronic hepatitis C. Gastroenterol Clin North Am 1994; 23: 603-613.
2. Seeff LB, Buskell-Bales Z, Wright EC et al. Long term mortality after transfusion-associated non-A, non-B hepatitis. New Engl J Med 1992; 327: 1906-1911.
3. Primary Liver Disease of Liver Transplant Recipients 1991, 1992 (From the UNOS Scientific Registry). UNOS Update 1993; 9: 27.
4. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989; 321: 1501-1506.
5. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects Dose Duration Hepatol 1996; 24: 778-789.
6. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B C hepatitis. Gastroenterology 1994; 106: 686-690.
7. Benhamou JP, Hopf U, Rizzetto M et al. Long-term lymphoblastoid interferon enhances sustained responses and improves histological activity up to 12 months post-treatment (abstr). Hepatology 1995; 22: 151A.
8. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa-2B regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-1562.
9. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. J Hepatol 1995; 23: 487-496.
10. Davis GL. Interferon treatment of cirrhotic patients with chronic hepatitis C: a logical intervention. Am J Gastroenterol 1994; 89: 658-660.
11. National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997; 26 (suppl 1): 2S-10S.
12. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural history of chronic hepatitis C. Am J Gastroenterol 1993; 88: 240-243.
13. Yano M, Kumada H, Kage M et al. The long-term pathologic evolution of chronic hepatitis C. Hepatology 1996; 23: 1334.
14. Davis GL, Lindsay K, Albrrcht J et al. Clinical predictors of response to recombinant alpha-interferon treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hep 1994; 1: 55-63.
15. Bennrtt WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimated cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865.
16. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
17. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 1994; 19: 1513-1520.
18. Shindo M, Arai K, Sokawa Y, Okuna T. Hepatic hepatitis C virus RNA as a predictor of long-term response to interferon-α therapy. Ann Intern Med 1995; 122: 586-591.
19. Sonnenberg FA, Pauker SG. DecisionMaker 6.0. In: Salamon R, Blum B, Jorgensen M, eds. MEDINFO 86, Part 2. Amsterdam: Elsevier Science Publishers, 1986: 1152.
20. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466.
21. Davis GL, Balart LA, Schiff ER et al. Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile, Clin Therapeut 1994; 16: 334-343.
22. Miholland AV, Wheeler SG, Heieck JJ. Medical assessment by a delphi group opinion technique. N Engl J Med 1973; 288: 1272-1275.
23. Red Book, 1995 Montvale New Jersey. Medical Economic Data 1995.
24. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716-721.
25. Gold MR, Siegel JE, Russell L, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
26. Reichard O, Glaumann H, Fryden A et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918-922.
27. Martinot-Peignoux M, Marcellin P, Pouteau M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-1056.
28. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C (editorial). J Hepatol 1994; 20: 1-3.
29. Davis GL, Lau JYN. Factors predictive of a favorable response to treatment of hepatitis C. Hepatology 1997; 26: 1228-1278.
30. Davis GL, Lau JYN, Urdea MS et al. Quantitative detection of hepatitis C virus (HCV) RNA by a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interfcron-treated patients. Hepatology 1994; 19: 1337-1341.
31. Fryback DG, Dasbach EJ, Klein R et al. The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making 1993: 13: 89-102.
32. Kim WR, Poterucha JJ, Hermans JE et al. Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis. Ann Intern Med 1997; 127: 866-874.
33. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon α-2b with or without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.